Drug reference
Fluocinolone
Corticosteroid · Ophthalmic Anti-inflammatory
Also known as Fluocinolone acetonide, Iluvien®
CorticosteroidOphthalmic Anti-inflammatory
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
Manufacturer advises avoid unless potential benefit outweighs risk—no information available.
FDA category + note
Mechanism
Fluocinolone, as a corticosteroid, exerts its effects by binding to intracellular glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects. It inhibits the release of inflammatory mediators and suppresses the migration of leukocytes.
Indications
Treatment of visual impairment associated with chronic diabetic macular oedema which is insufficiently responsive to available therapies (specialist use only)Prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (specialist use only)
Dosing
- Adult
- 190 micrograms, to be administered into the affected eye by intravitreal injection; concurrent administration to both eyes not recommended. For further information on pre-treatment, administration and repeat dosing, consult product literature.
Contraindications
- Active or suspected ocular infection
- Active or suspected peri-ocular infection
- Pre-existing glaucoma
- Raised baseline intra-ocular pressure
Side effects
Common
CataractDry eyeEye discomfortEye disordersGlaucomaHaemorrhageVision disorders
Serious
- Corneal deposits
- Eye inflammation
- Headache
- Optic nerve disorder
- Thromboembolism
- Central serous chorioretinopathy (rare risk)
Pregnancy & lactation
Pregnancy
Manufacturer advises avoid unless potential benefit outweighs risk—no information available.
Lactation
Manufacturer advises avoid unless essential.
Related guidelines
Other Corticosteroid drugs
Ask House about Fluocinolone
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Katzung, BNF, Harriet Lane·Verified: 2026-05-10 · House clinical team